한글목차

세계 mRNA 백신 시장 규모는 2033년까지 CAGR 10.5%로 성장할 것으로 예상됩니다.

잠재적 암 치료제로서 mRNA 백신에 대한 연구는 20년 이상 광범위하게 진행되어 왔지만, 지금까지 그 성과는 제한적이었습니다. 그러나 최근 들어 암 백신에 대한 연구 관심이 급증하고 있습니다. 이러한 급증은 면역관문억제제(immune checkpoint inhibitor)의 사용으로 특정 악성종양에 대해 뚜렷하고 지속적인 반응을 보인 것과 기술의 발전에 힘입은 바 큽니다. 모더나와 머크는 2023년 7월 26일 펨브롤리주맙(일명 키트루다)과 병용하는 맞춤형 백신 mRNA-4157(V940)의 임상 3상 시험 개시를 발표했습니다. 이 임상의 주요 평가항목은 이들 환자의 수술 후 무재발 생존율을 평가하는 것이며, 2029년까지 최종 결과가 나올 것으로 예상하고 있습니다.

세계의 mRNA 백신 시장을 조사했으며, 시장 개요, 시장 성장에 영향을 미치는 요인 및 시장 기회 분석, 시장 규모 추이 및 예측, 각 부문별/지역별 상세 분석, 경쟁 구도, 주요 기업 개요 등의 정보를 정리하여 전해드립니다.

목차

제1장 보고서 개요

제2장 주요 요약

제3장 시장 개요

• 주요 조사 결과
• 시장 역학
  • 시장 성장 촉진요인
  • 시장 성장 억제요인
  • 시장 기회
• COVID-19의 영향 분석
• Porter's Five Forces 분석
• PEST 분석

제4장 mRNA 백신 시장 분석 : 유형별

• 주요 조사 결과
• 시장의 매력 지수
• 시장 규모 추이와 예측
• 자기 증폭형 mRNA 기반 백신
• 기존 비증폭 mRNA 기반 백신

제5장 mRNA 백신 시장 분석 : 용도별

• 주요 조사 결과
• 시장의 매력 지수
• 시장 규모 추이와 예측
• 암
• 감염증
• 자가면역질환
• 기타

제6장 mRNA 백신 시장 분석 : 최종사용자별

• 주요 조사 결과
• 시장의 매력 지수
• 시장 규모 추이와 예측
• 병원 및 진료소
• 연구기관
• 기타

제7장 mRNA 백신 시장 분석 : 지역별

• 주요 조사 결과
• 시장 규모 추이와 예측

제8장 북미의 mRNA 백신 시장 분석

제9장 유럽의 mRNA 백신 시장 분석

제10장 아시아태평양의 mRNA 백신 시장 분석

제11장 라틴아메리카의 mRNA 백신 시장 분석

제12장 중동 및 아프리카의 mRNA 백신 시장 분석

제13장 기업 개요

• 경쟁 구도
• 전략적 전망
• BioNTech SE
• GSK plc
• Daiichi Sankyo
• Ethris GmbH
• AIM Vaccine
• Arcturus Therapeutics Inc.
• CureVac
• AstraZeneca
• Sanofi
• Sino Biopharmaceutical Co., Ltd.

제14장 결론 및 제안

• Visiongain의 결론
• 시장 진출기업에 대한 제안

영문목차

The global mRNA Vaccines market is projected to grow at a CAGR of 10.5% by 2033.

“The mRNA Vaccines Market Report 2023-2033”: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Extensive research has been conducted on mRNA vaccines as potential cancer therapeutics for a period exceeding two decades, yielding limited success. In recent times, there has been a notable surge in research attention towards cancer vaccines. This surge has been prompted by the remarkable and enduring responses witnessed in certain malignancies through the use of immune checkpoint inhibitors, as well as advancements in technology. The initiation of a phase 3 clinical trial for the personalised vaccine mRNA-4157 (also referred to as V940) in conjunction with pembrolizumab (commonly known as Keytruda) was announced by Moderna and Merck on 26 July 2023. This trial aims to evaluate the efficacy of the combination therapy in high-risk patients who have previously undergone surgical intervention for melanoma. The objective of the trial is to recruit a total of 1,089 patients who are at stages IIb to IV. The primary endpoint of the trial is to assess the post-surgical recurrence-free survival of these patients. The conclusive outcomes are anticipated to be available by the year 2029.

What Questions Should You Ask before Buying a Market Research Report?

• How is the mRNA vaccines market evolving?
• What is driving and restraining the mRNA vaccines market?
• How will each mRNA vaccines submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2033?
• How will the market shares for each mRNA vaccines submarket develop from 2023 to 2033?
• What will be the main driver for the overall market from 2023 to 2033?
• Will leading mRNA vaccines markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• How will the market shares of the national markets change by 2033 and which geographical region will lead the market in 2033?
• Who are the leading players and what are their prospects over the forecast period?
• What are the mRNA vaccines projects for these leading companies?
• How will the industry evolve during the period between 2023 and 2033? What are the implications of

mRNA vaccines projects taking place now and over the next 10 years?

• Is there a greater need for product commercialisation to further scale the mRNA vaccines market?
• Where is the mRNA vaccines market heading and how can you ensure you are at the forefront of the market?
• What are the best investment options for new product and service lines?
• What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the mRNA vaccines market today, and over the next 10 years:

• Our 215-page report provides 93 tables and 130 charts/graphs exclusively to you
• The report highlights key lucrative areas in the industry so you can target them - NOW
• It contains in-depth analysis of global, regional and national sales and growth
• It highlights for you the key successful trends, changes and revenue projections made by your competitors.

This report tells you TODAY how the mRNA vaccines market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2033 and other analyses reveal commercial prospects

• In addition to revenue forecasting to 2033, our new study provides you with recent results, growth rates, and market shares
• You will find original analyses, with business outlooks and developments
• Discover qualitative analyses (including market dynamics, drivers, opportunities, and restraints), Porter's Five Forces Analysis, PEST Analysis and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, ""V" ", "L", "W" and "U" are discussed in this report.

Segments Covered in the Report:

Vaccine Type

• Self-amplifying mRNA-based Vaccines
• Conventional Non-amplifying mRNA-based Vaccines

Application

• Cancer
• Infectious Disease
• Autoimmune Diseases
• Others

End-users

• Hospitals and Clinics
• Research Organisations
• Others

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 22 leading national markets:

North America

• U.S
• Canada

Europe

• Germany
• UK
• France
• Italy
• Spain
• Russia
• Rest of Europe

Asia Pacific

• Japan
• China
• India
• Australia
• South Korea
• South-East Asia
• Rest of Asia Pacific

Latin America

• Brazil
• Mexico
• Rest of Latin America

MEA

• GCC
• South Africa
• Rest of MEA

The report also includes profiles and for some of the leading companies in the mRNA Vaccines Market, 2023 to 2033, with a focus on this segment of these companies' operations.

Leading companies and the potential for market growth:

Overall world revenue for mRNA Vaccines Market, 2023 to 2033 in terms of value the market will surpass US$11,700.0 million in 2023, our work calculates. We predict strong revenue growth through to 2033. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the “mRNA Vaccines Market, 2023 to 2033” report help you?

In summary, our 210+ page report provides you with the following knowledge:

• Revenue forecasts to 2033 for mRNA Vaccines Market 2023 to 2033, with forecasts for Vaccine type, application, and end-users, each forecast at a global and regional level - discover the industry's prospects, finding the most lucrative places for investments and revenues.
• Revenue forecasts to 2033 for five regional and 22 key national markets - See forecasts for the mRNA Vaccines Market, 2023 to 2033 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
• Prospects for established firms and those seeking to enter the market - including company profiles for 12 of the major companies involved in the mRNA Vaccines Market, 2023 to 2033.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else

With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Our study is for everybody needing commercial analyses for the mRNA Vaccines Market 2023 to 2033, market-leading companies. You will find data, trends and predictions.

Table of Contents

1 Report Overview

• 1.1 Objectives of the Study
• 1.2 Introduction to mRNA Vaccines Market
• 1.3 What This Report Delivers
• 1.4 Why You Should Read This Report
• 1.5 Key Questions Answered by This Analytical Report Include:
• 1.6 Who is This Report For?
• 1.7 Methodology
  • 1.7.1 Market Definitions
  • 1.7.2 Market Evaluation & Forecasting Methodology
  • 1.7.3 Data Validation
    • 1.7.3.1 Primary Research
    • 1.7.3.2 Secondary Research
• 1.8 Frequently Asked Questions (FAQs)
• 1.9 Associated Visiongain Reports
• 1.10 About Visiongain

2 Executive Summary

3 Market Overview

• 3.1 Key Findings
• 3.2 Market Dynamics
  • 3.2.1 Market Driving Factors
    • 3.2.1.1 Growing Diverse Applications of mRNA Post COVID-19 Vaccine Success
    • 3.2.1.2 Significant Research Funding to Boost Market Growth
    • 3.2.1.3 Technological Advances Driving the Market Growth
    • 3.2.1.4 Rising mRNA Vaccine-based Clinical Trials
  • 3.2.2 Market Restraining Factors
    • 3.2.2.1 Scalability and Cost-Effectiveness is Still a Major Bottleneck
    • 3.2.2.2 Significant Storage Challenges in Low-income Countries Likely to Challenge Industry Growth
  • 3.2.3 Market Opportunities
    • 3.2.3.1 mRNA Cancer Vaccines
    • 3.2.3.2 Analytics, Machine Learning and Cloud Data Warehousing
• 3.3 COVID-19 Impact Analysis
• 3.4 Porter's Five Forces Analysis
  • 3.4.1 Supplier Power
  • 3.4.2 Buyer Power
  • 3.4.3 Competitive Rivalry
  • 3.4.4 Threat from Substitutes
  • 3.4.5 Threat of New Entrants
• 3.5 PEST Analysis
  • 3.5.1 Political Factors
  • 3.5.2 Economic Factors
  • 3.5.3 Social Factors
  • 3.5.4 Technological Factors

4 mRNA Vaccines Market Analysis by Vaccine Type

• 4.1 Key Findings
• 4.2 Vaccine Type Segment: Market Attractiveness Index
• 4.3 mRNA Vaccines Market Size Estimation and Forecast by Vaccine Type
• 4.4 Self-amplifying mRNA-based Vaccines
  • 4.4.1 Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
  • 4.4.2 Market Share by Region, 2023 & 2033 (%)
• 4.5 Conventional Non-amplifying mRNA-based Vaccines
  • 4.5.1 Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
  • 4.5.2 Market Share by Region, 2023 & 2033 (%)

5 mRNA Vaccines Market Analysis by Application

• 5.1 Key Findings
• 5.2 Application Segment: Market Attractiveness Index
• 5.3 mRNA Vaccines Market Size Estimation and Forecast by Application
• 5.4 Cancer
  • 5.4.1 Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
  • 5.4.2 Market Share by Region, 2023 & 2033 (%)
• 5.5 Infectious Disease
  • 5.5.1 Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
  • 5.5.2 Market Share by Region, 2023 & 2033 (%)
• 5.6 Autoimmune Diseases
  • 5.6.1 Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
  • 5.6.2 Market Share by Region, 2023 & 2033 (%)
• 5.7 Others
  • 5.7.1 Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
  • 5.7.2 Market Share by Region, 2023 & 2033 (%)

6 mRNA Vaccines Market Analysis by End-users

• 6.1 Key Findings
• 6.2 End-users Segment: Market Attractiveness Index
• 6.3 mRNA Vaccines Market Size Estimation and Forecast by End-users
• 6.4 Hospitals and Clinics
  • 6.4.1 Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
  • 6.4.2 Market Share by Region, 2023 & 2033 (%)
• 6.5 Research Organisations
  • 6.5.1 Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
  • 6.5.2 Market Share by Region, 2023 & 2033 (%)
• 6.6 Others
  • 6.6.1 Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
  • 6.6.2 Market Share by Region, 2023 & 2033 (%)

7 mRNA Vaccines Market Analysis by Region

• 7.1 Key Findings
• 7.2 Regional Market Size Estimation and Forecast

8 North America mRNA Vaccines Market Analysis

• 8.1 Key Findings
• 8.2 North America mRNA Vaccines Market Attractiveness Index
• 8.3 North America mRNA Vaccines Market by Country, 2023, 2028 & 2033 (US$ Million)
• 8.4 North America mRNA Vaccines Market Size Estimation and Forecast by Country
• 8.5 North America mRNA Vaccines Market Size Estimation and Forecast by Vaccine Type
• 8.6 North America mRNA Vaccines Market Size Estimation and Forecast by Application
• 8.7 North America mRNA Vaccines Market Size Estimation and Forecast by End-users
• 8.8 U.S. mRNA Vaccines Market Analysis
• 8.9 Canada mRNA Vaccines Market Analysis

9 Europe mRNA Vaccines Market Analysis

• 9.1 Key Findings
• 9.2 Europe mRNA Vaccines Market Attractiveness Index
• 9.3 Europe mRNA Vaccines Market by Country, 2023, 2028 & 2033 (US$ Million)
• 9.4 Europe mRNA Vaccines Market Size Estimation and Forecast by Country
• 9.5 Europe mRNA Vaccines Market Size Estimation and Forecast by Vaccine Type
• 9.6 Europe mRNA Vaccines Market Size Estimation and Forecast by Application
• 9.7 Europe mRNA Vaccines Market Size Estimation and Forecast by End-users
• 9.8 Germany mRNA Vaccines Market Analysis
• 9.9 UK mRNA Vaccines Market Analysis
• 9.10 France mRNA Vaccines Market Analysis
• 9.11 Italy mRNA Vaccines Market Analysis
• 9.12 Spain mRNA Vaccines Market Analysis
• 9.13 Russia mRNA Vaccines Market Analysis
• 9.14 Rest of Europe mRNA Vaccines Market Analysis

10 Asia Pacific mRNA Vaccines Market Analysis

• 10.1 Key Findings
• 10.2 Asia Pacific mRNA Vaccines Market Attractiveness Index
• 10.3 Asia Pacific mRNA Vaccines Market by Country, 2023, 2028 & 2033 (US$ Million)
• 10.4 Asia Pacific mRNA Vaccines Market Size Estimation and Forecast by Country
• 10.5 Asia Pacific mRNA Vaccines Market Size Estimation and Forecast by Vaccine Type
• 10.6 Asia Pacific mRNA Vaccines Market Size Estimation and Forecast by Application
• 10.7 Asia Pacific mRNA Vaccines Market Size Estimation and Forecast by End-users
• 10.8 Japan mRNA Vaccines Market Analysis
• 10.9 China mRNA Vaccines Market Analysis
• 10.10 India mRNA Vaccines Market Analysis
• 10.11 Australia mRNA Vaccines Market Analysis
• 10.12 South Korea mRNA Vaccines Market Analysis
• 10.13 South-East Asia mRNA Vaccines Market Analysis
• 10.14 Rest of Asia Pacific mRNA Vaccines Market Analysis

11 Latin America mRNA Vaccines Market Analysis

• 11.1 Key Findings
• 11.2 Latin America mRNA Vaccines Market Attractiveness Index
• 11.3 Latin America mRNA Vaccines Market by Country, 2023, 2028 & 2033 (US$ Million)
• 11.4 Latin America mRNA Vaccines Market Size Estimation and Forecast by Country
• 11.5 Latin America mRNA Vaccines Market Size Estimation and Forecast by Vaccine Type
• 11.6 Latin America mRNA Vaccines Market Size Estimation and Forecast by Application
• 11.7 Latin America mRNA Vaccines Market Size Estimation and Forecast by End-users
• 11.8 Brazil mRNA Vaccines Market Analysis
• 11.9 Mexico mRNA Vaccines Market Analysis
• 11.10 Rest of Latin America mRNA Vaccines Market Analysis

12 MEA mRNA Vaccines Market Analysis

• 12.1 Key Findings
• 12.2 MEA mRNA Vaccines Market Attractiveness Index
• 12.3 MEA mRNA Vaccines Market by Country, 2023, 2028 & 2033 (US$ Million)
• 12.4 MEA mRNA Vaccines Market Size Estimation and Forecast by Country
• 12.5 MEA mRNA Vaccines Market Size Estimation and Forecast by Vaccine Type
• 12.6 MEA mRNA Vaccines Market Size Estimation and Forecast by Application
• 12.7 MEA mRNA Vaccines Market Size Estimation and Forecast by End-users
• 12.8 GCC mRNA Vaccines Market Analysis
• 12.9 South Africa mRNA Vaccines Market Analysis
• 12.10 Rest of MEA mRNA Vaccines Market Analysis

13 Company Profiles

• 13.1 Pfizer Inc.
  • 13.1.1 Company Snapshot
  • 13.1.2 Company Overview
  • 13.1.3 Financial Analysis
    • 13.1.3.1 Net Revenue, 2015-2022
    • 13.1.3.2 Regional Market Shares, 2022
    • 13.1.3.3 R&D, 2015-2022
  • 13.1.4 Product/Pipeline Benchmarking
  • 13.1.5 Strategic Outlook
• 13.2 Moderna, Inc.
  • 13.2.1 Company Snapshot
  • 13.2.2 Company Overview
  • 13.2.3 Financial Analysis
    • 13.2.3.1 Net Revenue, 2016-2022
    • 13.2.3.2 R&D, 2016-2022
  • 13.2.4 Product/Pipeline Benchmarking
  • 13.2.5 Strategic Outlook
• 13.3 BioNTech SE
  • 13.3.1 Company Snapshot
  • 13.3.2 Company Overview
  • 13.3.3 Financial Analysis
    • 13.3.3.1 Net Revenue, 2018-2022
    • 13.3.3.2 R&D, 2018-2022
  • 13.3.4 Product/Pipeline Benchmarking
  • 13.3.5 Strategic Outlook
• 13.4 GSK plc
  • 13.4.1 Company Snapshot
  • 13.4.2 Company Overview
  • 13.4.3 Financial Analysis
    • 13.4.3.1 Net Revenue, 2015-2022
    • 13.4.3.2 Regional Market Shares, 2022
    • 13.4.3.3 R&D, 2015-2022
  • 13.4.4 Product/Pipeline Benchmarking
• 13.5 Daiichi Sankyo
  • 13.5.1 Company Snapshot
  • 13.5.2 Company Overview
  • 13.5.3 Product/Pipeline Benchmarking
  • 13.5.4 Strategic Outlook
• 13.6 Ethris GmbH
  • 13.6.1 Company Snapshot
  • 13.6.2 Company Overview
  • 13.6.3 Product/Pipeline Benchmarking
  • 13.6.4 Strategic Outlook
• 13.7 AIM Vaccine
  • 13.7.1 Company Snapshot
  • 13.7.2 Company Overview
  • 13.7.3 Product/Pipeline Benchmarking
  • 13.7.4 Strategic Outlook
• 13.8 Arcturus Therapeutics Inc.
  • 13.8.1 Company Snapshot
  • 13.8.2 Company Overview
  • 13.8.3 Product/Pipeline Benchmarking
• 13.9 CureVac
  • 13.9.1 Company Snapshot
  • 13.9.2 Company Overview
  • 13.9.3 Product/Pipeline Benchmarking
  • 13.9.4 Strategic Outlook
• 13.10 AstraZeneca
  • 13.10.1 Company Snapshot
  • 13.10.2 Company Overview
  • 13.10.3 Financial Analysis
    • 13.10.3.1 Net Revenue, 2015-2022
    • 13.10.3.2 Regional Market Shares, 2022
    • 13.10.3.3 R&D, 2015-2022
  • 13.10.4 Product/Pipeline Benchmarking
  • 13.10.5 Strategic Outlook
• 13.11 Sanofi
  • 13.11.1 Company Snapshot
  • 13.11.2 Company Overview
  • 13.11.3 Financial Analysis
    • 13.11.3.1 Net Revenue, 2018-2022
    • 13.11.3.2 Regional Market Shares, 2022
    • 13.11.3.3 R&D, 2018-2022
  • 13.11.4 Product/Pipeline Benchmarking
• 13.12 Sino Biopharmaceutical Co., Ltd.
  • 13.12.1 Company Snapshot
  • 13.12.2 Company Overview
  • 13.12.3 Product/Pipeline Benchmarking

14 Conclusion and Recommendations

• 14.1 Concluding Remarks from Visiongain
• 14.2 Recommendations for Market Players